$德康医疗(DXCM)$  没有展望的信息   DexCom (NASDAQ:DXCM): Q4 EPS of -$0.09 beats by $0.01.
Revenue of $171.2M (+30.9% Y/Y) beats by $3.23M.

Total revenue grew to $171.2 million for the fourth quarter of 2016, an increase of 31% from the $130.8 million in total revenue for the same quarter in 2015.

Total revenue grew to $573.3 million for the twelve months ended December 31, 2016, an increase of 43% from the $402.0 millionin total revenue for the comparable period in 2015.

DexCom's worldwide patient base increased to approximately 200,000 patients by the end of 2016, up from an estimated 140,000 at the end of 2015.

GAAP net loss was $7.4 million, or $0.09 per share, for the fourth quarter of 2016, compared to GAAP net income of $1.5 million, or $0.02 per share, for the comparable period in 2015.